John Watson,
Director,
Promega Corporation
Dr. Watson has a B.S. in Genetics and Cell Biology from the University of Minnesota, an M.S. in Bacteriology; and a Ph.D. in Biomolecular Chemistry from the University of Wisconsin. After a clinical postdoctoral fellowship in Clinical Chemistry and Molecular Diagnostics he became Director of Molecular Diagnostics at Epicentre Technologies where he led R&D and Marketing efforts for their clinical products. Subsequent positions have included Director of Cellular Analysis at Promega Corporation, and Director of Marketing for the PanVera division Vertex Pharmaceuticals (becoming Director of Marketing for Drug Screening at Invitrogen after the acquisition). He also managed R&D, applications and Marketing for the FTIR instrument division of Thermo Electron Corporation.
|
|
Hall 2- Cell Based Assays in Clinical Diagnostics: Applications to Neutralizing Antibody Assays, Pharmacogenomics, and Personalized MedicineFriday, 12 September 2014 at 11:35 Add to Calendar ▼2014-09-12 11:35:002014-09-12 12:35:00Europe/LondonHall 2- Cell Based Assays in Clinical Diagnostics: Applications to Neutralizing Antibody Assays, Pharmacogenomics, and Personalized MedicineDrug Discovery India 2014 in MumbaiMumbaiSELECTBIOenquiries@selectbiosciences.com
|